Agios Pharmaceuticals (AGIO) Earnings Date, Estimates & Call Transcripts → Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (From Banyan Hill Publishing) (Ad) Free AGIO Stock Alerts $32.84 +0.08 (+0.24%) (As of 11:31 AM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Earnings SummaryUpcoming Earnings DateMay. 2Before Market OpensConfirmedActual EPS (Feb. 15) -$1.72 Missed By -$0.08 Consensus EPS (Feb. 15) -$1.64 Read Call TranscriptListen to CallLatest SEC 10-Q Filing Get Agios Pharmaceuticals Earnings AlertsEnter your email address below to receive the latest news and earnings results for AGIO and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueAGIO Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.AGIO Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Banyan Hill PublishingNvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. Agios Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242($1.69)($1.55)($1.62)Q2 20242($1.71)($1.52)($1.62)Q3 20242($1.52)($1.48)($1.50)Q4 20242($1.46)($1.44)($1.45)FY 20248($6.38)($5.99)($6.19)Q1 20251($1.45)($1.45)($1.45)Q2 20251($1.42)($1.42)($1.42)Q3 20251($1.39)($1.39)($1.39)Q4 20251($1.31)($1.31)($1.31)FY 20254($5.57)($5.57)($5.57)AGIO Earnings Date and InformationAgios Pharmaceuticals last announced its quarterly earnings results on February 15th, 2024. The biopharmaceutical company reported ($1.72) earnings per share for the quarter, missing the consensus estimate of ($1.64) by $0.08. The company had revenue of $7.10 million for the quarter, compared to the consensus estimate of $7.80 million. Its revenue was up 65.1% on a year-over-year basis. Agios Pharmaceuticals has generated ($6.34) earnings per share over the last year (($6.34) diluted earnings per share). Earnings for Agios Pharmaceuticals are expected to decrease in the coming year, from ($5.29) to ($5.87) per share. Agios Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, May 2nd, 2024. Agios Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:00 AM Eastern. Interested parties can register for or listen to the call.. Read More Agios Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/2/2024Confirmed)------- 2/15/2024Q4 2023($1.64)($1.72)($0.08)($1.72)$7.80 million$7.10 million 11/2/2023Q3 2023($1.69)($1.64)+$0.05($1.64)$7.73 million$7.40 million8/3/2023Q2 2023($1.60)($1.51)+$0.09($1.51)$6.46 million$6.70 million 5/4/2023Q1 2023($1.72)($1.47)+$0.25($1.47)$5.23 million$5.61 million 2/23/2023Q4 2022($1.59)$0.67+$2.26$0.67$4.42 million$4.31 million11/3/2022Q3 2022($1.75)($1.49)+$0.26($1.49)$5.24 million$3.52 million Get the Latest News and Ratings for AGIO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/4/2022Q2 2022($1.78)($1.68)+$0.10($1.68)$2.86 million$5.58 million 5/5/2022Q1 2022($1.85)($1.74)+$0.11($1.74)$2.71 million$0.83 million 2/24/2022Q4 2021($1.71)($1.81)($0.10)($1.88)$0.56 million- 11/3/2021Q3 2021($1.57)($1.48)+$0.09($1.40)$2.34 million- 7/28/2021Q2 2021($1.39)($1.44)($0.05)($1.31)-- Agios Pharmaceuticals Earnings - Frequently Asked Questions When is Agios Pharmaceuticals's earnings date? Agios Pharmaceuticals has confirmed that its next quarterly earnings data will be published on Thursday, May 2nd, 2024. Learn more on AGIO's earnings history. Did Agios Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Agios Pharmaceuticals (NASDAQ:AGIO) missed the analysts' consensus estimate of ($1.64) by $0.08 with a reported earnings per share (EPS) of ($1.72). Learn more on analysts' earnings estimate vs. AGIO's actual earnings. How can I listen to Agios Pharmaceuticals's earnings conference call? The conference call for Agios Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call How can I read Agios Pharmaceuticals's conference call transcript? The conference call transcript for Agios Pharmaceuticals's latest earnings report can be read online. Read Transcript How can I view Agios Pharmaceuticals's earnings report? Agios Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Agios Pharmaceuticals generate each year? Agios Pharmaceuticals (NASDAQ:AGIO) has a recorded annual revenue of $26.82 million. How much profit does Agios Pharmaceuticals generate each year? Agios Pharmaceuticals (NASDAQ:AGIO) has a recorded net income of -$352.09 million. AGIO has generated -$6.34 earnings per share over the last four quarters. What is Agios Pharmaceuticals's EPS forecast for next year? Agios Pharmaceuticals's earnings are expected to decrease from ($5.29) per share to ($5.87) per share in the next year. More Earnings Resources from MarketBeat Related Companies: SNDX Earnings SDGR Earnings CPRX Earnings GPCR Earnings GERN Earnings AMRX Earnings SUPN Earnings AVDL Earnings HRMY Earnings GLPG Earnings Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (NASDAQ:AGIO) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold GroupElon Musk Secret Crypto Plot ExposedCrypto 101 MediaHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Agios Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.